Schizophrenia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major schizophrenia markets reached a value of US$ 9,480.4 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 15,236.9 Million by 2034, exhibiting a growth rate (CAGR) of 4.4% during 2024-2034.
The schizophrenia market has been comprehensively analyzed in IMARC's new report titled "Schizophrenia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Schizophrenia is a complex, chronic mental health disorder that often develops in late adolescence or early childhood and is characterized by disruptions in perceptions, thought processes, emotional responsiveness, and social interactions. The early onset of the disease, along with its chronic course, make it a disabling condition for several patients and their families. Schizophrenia patients usually tend to suffer from an array of symptoms, including hallucinations, delusions, disorganized speech or behavior, and impaired cognitive ability. Other symptoms tend to comprise trouble with concentration and movement-related disorders, among others. Schizophrenia patients are usually advised to undergo a psychological evaluation and a complete medical exam. Delusions or hallucinations alone can often be enough to lead to a diagnosis of schizophrenia. Additionally, a urine or blood test can be performed to eliminate alcohol or drug abuse as the cause of the symptoms. Besides this, magnetic resonance imaging (MRI) or computed tomography (CT) can also be used to eradicate the possibility of a brain tumor. An early diagnosis greatly improves a person's chances of recovering from the illness, reducing episodes of psychosis, and coping with psychotic experiences.
The rising incidences of mental illnesses owing to genetic dispositions, specific chemical imbalances in the brain, substance abuse, and psychosocial variables are primarily driving the global schizophrenia market. In addition to this, the growing investments in digital and telecommunication solutions by government bodies and NGOs to promote self-care and mental health awareness are further bolstering the market growth. Moreover, the emerging popularity of injectable-based schizophrenia medications, particularly long-acting injectables owing to their associated benefits, such as effective long-term relapse prevention, increased patient compliance, ease of administration, and fewer adverse effects as compared to oral treatments is also creating a positive outlook for the market. Besides this, several key players are making significant investments in developing second-generation antipsychotics, such as serotonin and histamine, to prevent amphetamine-induced behavioral changes in patients. This, in turn, is acting as another growth-inducing factor. Additionally, the escalating utilization of high-content single-cell screenings to develop efficacious compounds for new schizophrenia drugs is further augmenting the market growth. They are cost-effective and time-saving alternative for introducing innovative drugs that can be supplied to small-scale clinics and other healthcare providers using this treatment repurposing strategy. Apart from this, the inflating demand for novel drugs with increased efficacy that do not have any adverse reactions on the patient's safety and well-being is expected to drive the schizophrenia market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the schizophrenia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for schizophrenia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the schizophrenia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the schizophrenia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the schizophrenia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current schizophrenia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the schizophrenia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the schizophrenia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the schizophrenia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the size of the schizophrenia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of schizophrenia?
What will be the growth rate of patients across the seven major markets?
Schizophrenia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for schizophrenia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the schizophrenia market?
The schizophrenia market has been comprehensively analyzed in IMARC's new report titled "Schizophrenia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Schizophrenia is a complex, chronic mental health disorder that often develops in late adolescence or early childhood and is characterized by disruptions in perceptions, thought processes, emotional responsiveness, and social interactions. The early onset of the disease, along with its chronic course, make it a disabling condition for several patients and their families. Schizophrenia patients usually tend to suffer from an array of symptoms, including hallucinations, delusions, disorganized speech or behavior, and impaired cognitive ability. Other symptoms tend to comprise trouble with concentration and movement-related disorders, among others. Schizophrenia patients are usually advised to undergo a psychological evaluation and a complete medical exam. Delusions or hallucinations alone can often be enough to lead to a diagnosis of schizophrenia. Additionally, a urine or blood test can be performed to eliminate alcohol or drug abuse as the cause of the symptoms. Besides this, magnetic resonance imaging (MRI) or computed tomography (CT) can also be used to eradicate the possibility of a brain tumor. An early diagnosis greatly improves a person's chances of recovering from the illness, reducing episodes of psychosis, and coping with psychotic experiences.
The rising incidences of mental illnesses owing to genetic dispositions, specific chemical imbalances in the brain, substance abuse, and psychosocial variables are primarily driving the global schizophrenia market. In addition to this, the growing investments in digital and telecommunication solutions by government bodies and NGOs to promote self-care and mental health awareness are further bolstering the market growth. Moreover, the emerging popularity of injectable-based schizophrenia medications, particularly long-acting injectables owing to their associated benefits, such as effective long-term relapse prevention, increased patient compliance, ease of administration, and fewer adverse effects as compared to oral treatments is also creating a positive outlook for the market. Besides this, several key players are making significant investments in developing second-generation antipsychotics, such as serotonin and histamine, to prevent amphetamine-induced behavioral changes in patients. This, in turn, is acting as another growth-inducing factor. Additionally, the escalating utilization of high-content single-cell screenings to develop efficacious compounds for new schizophrenia drugs is further augmenting the market growth. They are cost-effective and time-saving alternative for introducing innovative drugs that can be supplied to small-scale clinics and other healthcare providers using this treatment repurposing strategy. Apart from this, the inflating demand for novel drugs with increased efficacy that do not have any adverse reactions on the patient's safety and well-being is expected to drive the schizophrenia market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the schizophrenia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for schizophrenia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the schizophrenia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the schizophrenia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the schizophrenia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current schizophrenia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the schizophrenia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the schizophrenia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the schizophrenia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the size of the schizophrenia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of schizophrenia?
What will be the growth rate of patients across the seven major markets?
Schizophrenia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for schizophrenia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the schizophrenia market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SCHIZOPHRENIA - INTRODUCTION
4.1 Overview
4.2 Epidemiology (?2018-2023?) and Forecast (?2024-2034?)
4.3 Market Overview (?2018-2023?) and Forecast (?2024-2034?)
4.4 Competitive Intelligence
5 SCHIZOPHRENIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 SCHIZOPHRENIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (?2018-2023?)
7.2.2 Epidemiology Forecast (?2024-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (?2018-2023?)
7.3.2 Epidemiology Forecast (?2024-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (?2018-2023?)
7.4.2 Epidemiology Forecast (?2024-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (?2018-2023?)
7.5.2 Epidemiology Forecast (?2024-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (?2018-2023?)
7.6.2 Epidemiology Forecast (?2024-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (?2018-2023?)
7.7.2 Epidemiology Forecast (?2024-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (?2018-2023?)
7.8.2 Epidemiology Forecast (?2024-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (?2018-2023?)
7.9.2 Epidemiology Forecast (?2024-2034?)
8 SCHIZOPHRENIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 SCHIZOPHRENIA - UNMET NEEDS
10 SCHIZOPHRENIA - KEY ENDPOINTS OF TREATMENT
11 SCHIZOPHRENIA - MARKETED PRODUCTS
11.1 List of Schizophrenia Marketed Drugs Across the Top 7 Markets
11.1.1 Aripiprazole – Otsuka Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Asenapine - Organon
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Brexpiprazole - Otsuka Pharmaceuticals
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Cariprazine - Gedeon Richter
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Lurasidone - Sumitomo Pharma
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs and the complete list has been provided in the report.
12 SCHIZOPHRENIA - PIPELINE DRUGS
12.1 List of Schizophrenia Pipeline Drugs Across the Top 7 Markets
12.1.1 Deudextromethorphan - Otsuka Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 SKL 15508 - SK biopharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 TAK 041 - Takeda
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Luvadaxistat - Takeda
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 SEP-363856 - Otsuka Pharmaceuticals
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report.
13. SCHIZOPHRENIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 SCHIZOPHRENIA - MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Schizophrenia - Market Size
14.2.1.1 Market Size (?2018-2023?)
14.2.1.2 Market Forecast (?2024-2034?)
14.2.2 Schizophrenia - Market Size by Therapies
14.2.2.1 Market Size by Therapies (?2018-2023?)
14.2.2.2 Market Forecast by Therapies (?2024-2034?)
14.3 Market Scenario - United States
14.3.1 Schizophrenia - Market Size
14.3.1.1 Market Size (?2018-2023?)
14.3.1.2 Market Forecast (?2024-2034?)
14.3.2 Schizophrenia - Market Size by Therapies
14.3.2.1 Market Size by Therapies (?2018-2023?)
14.3.2.2 Market Forecast by Therapies (?2024-2034?)
14.3.3 Schizophrenia - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Schizophrenia - Market Size
14.4.1.1 Market Size (?2018-2023?)
14.4.1.2 Market Forecast (?2024-2034?)
14.4.2 Schizophrenia - Market Size by Therapies
14.4.2.1 Market Size by Therapies (?2018-2023?)
14.4.2.2 Market Forecast by Therapies (?2024-2034?)
14.4.3 Schizophrenia - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Schizophrenia - Market Size
14.5.1.1 Market Size (?2018-2023?)
14.5.1.2 Market Forecast (?2024-2034?)
14.5.2 Schizophrenia - Market Size by Therapies
14.5.2.1 Market Size by Therapies (?2018-2023?)
14.5.2.2 Market Forecast by Therapies (?2024-2034?)
14.5.3 Schizophrenia - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Schizophrenia - Market Size
14.6.1.1 Market Size (?2018-2023?)
14.6.1.2 Market Forecast (?2024-2034?)
14.6.2 Schizophrenia - Market Size by Therapies
14.6.2.1 Market Size by Therapies (?2018-2023?)
14.6.2.2 Market Forecast by Therapies (?2024-2034?)
14.6.3 Schizophrenia - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Schizophrenia - Market Size
14.7.1.1 Market Size (?2018-2023?)
14.7.1.2 Market Forecast (?2024-2034?)
14.7.2 Schizophrenia - Market Size by Therapies
14.7.2.1 Market Size by Therapies (?2018-2023?)
14.7.2.2 Market Forecast by Therapies (?2024-2034?)
14.7.3 Schizophrenia - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Schizophrenia - Market Size
14.8.1.1 Market Size (?2018-2023?)
14.8.1.2 Market Forecast (?2024-2034?)
14.8.2 Schizophrenia - Market Size by Therapies
14.8.2.1 Market Size by Therapies (?2018-2023?)
14.8.2.2 Market Forecast by Therapies (?2024-2034?)
14.8.3 Schizophrenia - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Schizophrenia - Market Size
14.9.1.1 Market Size (?2018-2023?)
14.9.1.2 Market Forecast (?2024-2034?)
14.9.2 Schizophrenia - Market Size by Therapies
14.9.2.1 Market Size by Therapies (?2018-2023?)
14.9.2.2 Market Forecast by Therapies (?2024-2034?)
14.9.3 Schizophrenia - Access and Reimbursement Overview
15 SCHIZOPHRENIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 SCHIZOPHRENIA MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SCHIZOPHRENIA - INTRODUCTION
4.1 Overview
4.2 Epidemiology (?2018-2023?) and Forecast (?2024-2034?)
4.3 Market Overview (?2018-2023?) and Forecast (?2024-2034?)
4.4 Competitive Intelligence
5 SCHIZOPHRENIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 SCHIZOPHRENIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (?2018-2023?)
7.2.2 Epidemiology Forecast (?2024-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (?2018-2023?)
7.3.2 Epidemiology Forecast (?2024-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (?2018-2023?)
7.4.2 Epidemiology Forecast (?2024-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (?2018-2023?)
7.5.2 Epidemiology Forecast (?2024-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (?2018-2023?)
7.6.2 Epidemiology Forecast (?2024-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (?2018-2023?)
7.7.2 Epidemiology Forecast (?2024-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (?2018-2023?)
7.8.2 Epidemiology Forecast (?2024-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (?2018-2023?)
7.9.2 Epidemiology Forecast (?2024-2034?)
8 SCHIZOPHRENIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 SCHIZOPHRENIA - UNMET NEEDS
10 SCHIZOPHRENIA - KEY ENDPOINTS OF TREATMENT
11 SCHIZOPHRENIA - MARKETED PRODUCTS
11.1 List of Schizophrenia Marketed Drugs Across the Top 7 Markets
11.1.1 Aripiprazole – Otsuka Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Asenapine - Organon
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Brexpiprazole - Otsuka Pharmaceuticals
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Cariprazine - Gedeon Richter
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Lurasidone - Sumitomo Pharma
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs and the complete list has been provided in the report.
12 SCHIZOPHRENIA - PIPELINE DRUGS
12.1 List of Schizophrenia Pipeline Drugs Across the Top 7 Markets
12.1.1 Deudextromethorphan - Otsuka Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 SKL 15508 - SK biopharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 TAK 041 - Takeda
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Luvadaxistat - Takeda
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 SEP-363856 - Otsuka Pharmaceuticals
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report.
13. SCHIZOPHRENIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 SCHIZOPHRENIA - MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Schizophrenia - Market Size
14.2.1.1 Market Size (?2018-2023?)
14.2.1.2 Market Forecast (?2024-2034?)
14.2.2 Schizophrenia - Market Size by Therapies
14.2.2.1 Market Size by Therapies (?2018-2023?)
14.2.2.2 Market Forecast by Therapies (?2024-2034?)
14.3 Market Scenario - United States
14.3.1 Schizophrenia - Market Size
14.3.1.1 Market Size (?2018-2023?)
14.3.1.2 Market Forecast (?2024-2034?)
14.3.2 Schizophrenia - Market Size by Therapies
14.3.2.1 Market Size by Therapies (?2018-2023?)
14.3.2.2 Market Forecast by Therapies (?2024-2034?)
14.3.3 Schizophrenia - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Schizophrenia - Market Size
14.4.1.1 Market Size (?2018-2023?)
14.4.1.2 Market Forecast (?2024-2034?)
14.4.2 Schizophrenia - Market Size by Therapies
14.4.2.1 Market Size by Therapies (?2018-2023?)
14.4.2.2 Market Forecast by Therapies (?2024-2034?)
14.4.3 Schizophrenia - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Schizophrenia - Market Size
14.5.1.1 Market Size (?2018-2023?)
14.5.1.2 Market Forecast (?2024-2034?)
14.5.2 Schizophrenia - Market Size by Therapies
14.5.2.1 Market Size by Therapies (?2018-2023?)
14.5.2.2 Market Forecast by Therapies (?2024-2034?)
14.5.3 Schizophrenia - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Schizophrenia - Market Size
14.6.1.1 Market Size (?2018-2023?)
14.6.1.2 Market Forecast (?2024-2034?)
14.6.2 Schizophrenia - Market Size by Therapies
14.6.2.1 Market Size by Therapies (?2018-2023?)
14.6.2.2 Market Forecast by Therapies (?2024-2034?)
14.6.3 Schizophrenia - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Schizophrenia - Market Size
14.7.1.1 Market Size (?2018-2023?)
14.7.1.2 Market Forecast (?2024-2034?)
14.7.2 Schizophrenia - Market Size by Therapies
14.7.2.1 Market Size by Therapies (?2018-2023?)
14.7.2.2 Market Forecast by Therapies (?2024-2034?)
14.7.3 Schizophrenia - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Schizophrenia - Market Size
14.8.1.1 Market Size (?2018-2023?)
14.8.1.2 Market Forecast (?2024-2034?)
14.8.2 Schizophrenia - Market Size by Therapies
14.8.2.1 Market Size by Therapies (?2018-2023?)
14.8.2.2 Market Forecast by Therapies (?2024-2034?)
14.8.3 Schizophrenia - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Schizophrenia - Market Size
14.9.1.1 Market Size (?2018-2023?)
14.9.1.2 Market Forecast (?2024-2034?)
14.9.2 Schizophrenia - Market Size by Therapies
14.9.2.1 Market Size by Therapies (?2018-2023?)
14.9.2.2 Market Forecast by Therapies (?2024-2034?)
14.9.3 Schizophrenia - Access and Reimbursement Overview
15 SCHIZOPHRENIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 SCHIZOPHRENIA MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
